Country Market Data

It’s not enough to just own market data; you have to be able to understand and interpret it, too. That’s a much bigger task than it sounds; parameters like regulations, market stage and demand for Pharma and Consumer Health products can make data differ drastically from one country to country. Understanding those nuances can be very difficult.

 At CPC, we offer Country Data analyses to advise you on the most attractive Pharma and Healthcare Markets, the opportunities they offer and how to take the most advantage of them.

CIS/CEE Countries



The CIS (Commonwealth of Independent States) region is comprised of former Soviet Union member states; CEE stands for Central and Eastern Europe and is formed of countries from Southern, South-eastern and Eastern Europe. Most of them have Emerging Markets; the Russia Pharma and OTC Market is one of the most promising in terms of size and growth. Most of the CIS Markets have huge potential—having only existed since the dissolution of the USSR, these markets are young and require huge imports of Pharma and Consumer Health products. (More than 75% of the products in the region are imported.) In these countries, there is an urgent need for a bigger, improved and more specialised Healthcare system.

RussiaUkraineKazakhstanCzech RepublicPolandRomania


Despite the low development stage of the Healthcare infrastructure in many Asian countries, Asia is one of the areas with the most potential for Pharma and Consumer Health investors; these nations’ are very willing to improve their Healthcare and Pharma and Consumer Health systems and have numerous projected investments in those areas over the next few years. Cultural differences should not be discouraging in the face of the possibility of a very lucrative and successful investment.

IndonesiaThe PhilippinesThailandChinaMalaysiaIndiaVietnamSouth Korea

Latin America

The Latin American Healthcare Market has become a very appealing market due to its strong growth opportunities and regulatory developments, especially when it comes to long-term investments. The Mexican Pharma and OTC Market, for example, is the second largest in Latin America as well as one of the most attractive destinations for foreign manufacturers and investors. According to the experts from CPC, the combined Latin American Pharma and Consumer Health platform will have an estimated market value of more than US $105 billion by the year 2018.

Mexico ColombiaBrazil ArgentinaPeru


 In the next five years, the developed Pharma and OTC Markets in Europe are expected to grow much less due to a variety of factors: patent expiries, the sustained consequences of the global economic crisis, the increasingly specialist nature of many new medicines and an increasingly cautious approach to innovation in the region. Spending growth in the EU-5 countries (Germany, France, Spain, Italy and United Kingdom) will be negligible in aggregate as governments across the region continue to apply a range of austerity measures designed to shift usage to generics and restrict use of innovative launches. The mature Western pharmaceutical industry is now facing a challenging business environment and consequently shows slowed growth.

BeNeLuxNorth EuropeAustriaFranceGermanyItalyPortugalSpainSwitzerland




South Africa